ONCOLOGY Staff

Read this discussion to spot LEMS red flags tied to small cell lung cancer, avoid misdiagnosis, and follow antibody/EMG testing and screening steps.

Discover how PSMA PET sharpens staging, guides radioligand therapy sequencing, and tackles real‑world access hurdles in advanced prostate cancer.

Learn how ctDNA monitoring predicts breast cancer recurrence and detects ESR1/PIK3CA resistance, enabling earlier, personalized therapy switches.

Peter Martin, MD, focused on the collaborative meeting setting and where the MCL research field is headed.

Kami Maddocks, MD, discusses how the push to define high-risk MCL for clinical trials was a focus at the 2025 MCL workshop.

Michael Wang, MD, discusses the impact of the MCL Scientific Consortium on the lymphoma community.

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

C. Ola Landgren, MD, PhD, and Noopur Raje, MD, discussed results from the ADVANCE trial of DKRd in patients with newly diagnosed multiple myeloma.

A panel of experts gathered to discuss results from the MATTERHORN trial assessing durvalumab plus FLOT in gastric/GEJ cancer.

Expert teams debate cutting-edge lung cancer treatments, exploring trial data and innovative strategies for improving patient outcomes in NSCLC and SCLC.

Discover the latest breakthroughs in non-small cell lung cancer treatment from the 2025 WCLC, featuring competitive insights from leading experts.

Experts discussed how treatment should be sequenced for patients with small cell lung cancer who have brain metastases, highlighting recent clinical trial advancements and safety considerations.

Experts discuss the proper placement of Dato-DXd in the treatment of EGFR-mutated non–small cell lung cancer, comparing it with other potential treatments.

The latest advancements in bispecific antibodies and antibody-drug conjugates continue to improve the personalized treatment of advanced non-small cell lung cancer.

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer and their unique safety profiles.

Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.

Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

Two teams of lymphoma experts engage in a face-off competition, showcasing real-world updates, patient cases, and use of ASCT or CAR T-cell therapy.

An expert discusses the vital role of comprehensive genomic profiling in personalizing treatment for non-small cell lung cancer, enhancing patient outcomes.

Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.

New therapies for hepatobiliary cancers show promise, expanding treatment options for patients with advanced disease and challenging conditions.

Recent advancements in multiple myeloma treatment highlight the efficacy of daratumumab combined with VRd, showcasing improved outcomes and tolerability.

Experts discuss evolving therapies for EGFR-mutated metastatic NSCLC, comparing combination regimens and their impact on patient outcomes.

Explore the latest advancements in c-Met-targeted therapies for NSCLC, including optimal testing strategies and management of adverse events.

Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.